CAU
AXSM icon

Caxton Associates (UK)’s Axsome Therapeutics AXSM Stock Holding History

Caxton Associates (UK)’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
4,290
-21
-0.5% -$4.55K 0.02% 403
2026
Q1 		$729K Buy
+4,311
New +$745K 0.02% 443
2025
Q2 		– Sell
-2,629
Closed -$307K – 699
2025
Q1 		$307K Buy
+2,629
New +$300K 0.01% 625

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Caxton Associates (UK)'s AXSM Position: Q2 2026 in Review

Caxton Associates (UK) reduced its Axsome Therapeutics (AXSM) stake by 0.49% in Q2 2026, selling an estimated $4.55K and leaving 4,290 shares worth $1.05M. The position accounts for 0.02% of the portfolio, ranked #403.

Caxton Associates (UK) first reported a position in AXSM in Q1 2025 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Caxton Associates (UK) held 4,290 shares of Axsome Therapeutics worth $1.05M as of Q2 2026.
  • Caxton Associates (UK) sold 21 Axsome Therapeutics shares in Q2 2026, an estimated $4.55K.
  • Axsome Therapeutics made up 0.02% of Caxton Associates (UK)'s portfolio in Q2 2026, its #403 holding.
  • Caxton Associates (UK) first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.